Browsing Tag
BLINCYTO
4 posts
Amgen reports strong Q4 growth amid expanding product sales and biotech innovations
Amgen’s revenue growth for the fourth quarter of 2024 exceeded analyst expectations, reflecting the company’s expanding biopharmaceutical portfolio…
Amgen’s Blincyto gains EU approval for consolidation phase treatment in B-ALL
Amgen has received European Commission approval for Blincyto (blinatumomab) as part of consolidation therapy in adults with newly…
FDA approves Amgen’s BLINCYTO for expanded use in B-ALL treatment
Amgen (NASDAQ: AMGN) has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval…
EC grants expanded approval for Amgen’s BLINCYTO in pediatric acute lymphoblastic leukemia treatment
In a significant development for pediatric oncology, the European Commission (EC) has approved an expanded indication for Amgen’s…